Skip to main content Accessibility help
×
Home
Hostname: page-component-684899dbb8-662rr Total loading time: 0.364 Render date: 2022-05-27T22:22:56.613Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }

Response from GlaxoSmithKline

Published online by Cambridge University Press:  02 January 2018

F. Rockhold
Affiliation:
Glaxo Smith Kline, PO Box 13398, Five Moore Drive, Research Triangle Park, NC 27709-3398, USA
A. Metz
Affiliation:
Glaxo Smith Kline, PO Box 13398, Five Moore Drive, Research Triangle Park, NC 27709-3398, USA
P. Traber
Affiliation:
Glaxo Smith Kline, PO Box 13398, Five Moore Drive, Research Triangle Park, NC 27709-3398, USA
Rights & Permissions[Opens in a new window]

Abstract

Type
Columns
Copyright
Copyright © 2002 The Royal College of Psychiatrists 

Dr Healy responds to concerns raised by Markowitz (2001) about the potential for misinterpretation of the Donovan et al (2000) study. Markowitz points out that the patient populations receiving SSRIs and tricyclic antidepressants were not similar, and accordingly that comparisons of the effects of the two classes of antidepressants on suicide risk are not meaningful. Dr Healy suggests that there are data in the public domain bearing on this issue, citing the meta-analysis performed by Khan et al (2000) and data obtained from the US Food and Drug Administration. Khan et al found no difference in suicide or suicide attempts with the use of antidepressants compared with placebo. Dr Healy claims that suicides and suicide attempts during ‘washout rather than while on placebo’ invalidate the results of Dr Khan et al's analysis.

With respect to paroxetine, Dr Healy misstates the scope of the Khan et al meta-analysis, and the conclusions he draws lack scientific substantiation. Dr Healy fails to recognise that the exposure time of patients on paroxetine in the clinical studies was substantially different and far greater than that on placebo — under these circumstances an analysis of absolute numbers of patients with no consideration of time of exposure is not meaningful. Furthermore, contrary to Dr Healy's implication, the Khan et al report was not limited to randomised, placebo-controlled studies. In the case of paroxetine, the studies covered included open label extensions, studies without placebo arms, and studies that were not randomised. When one considers only the randomised, controlled portions of the placebo-controlled trials (excluding events occurring during placebo run-in) included in the Khanet al analysis, there are no statistically significant differences in suicides or suicide attempts between paroxetine and placebo, either in absolute numbers of patients or when adjusted for time of exposure.

Donovan et al caution about the conclusions that should be drawn from the study. They point out that physicians are following guidance to prescribe antidepressants that are purportedly ‘safer in overdose’ to patients who are perceived to be at greater risk of deliberate self-harm. Consistent with Dr Markowitz's comments, this prejudices against SSRIs when associations are made between their use and deliberate self-harm. Donovanet al also note that it is problematic attributing the cause of deliberate self-harm to antidepressant treatment when such behaviour occurs as a symptom of depressive illness itself and that establishment of cause and effect is ‘almost impossible’.

The ‘drug v. “true placebo” ’ analysis Dr Healy describes is not only scientifically invalid, but also misleading. Major depressive disorder is a potentially very serious illness associated with substantial morbidity, mortality, suicidal ideation, suicide attempts and completed suicide. Unwarranted conclusions about the use and risk of antidepressants, including paroxetine, do a disservice to patients and physicians.

Footnotes

EDITED BY MATTHEW HOTOPF

References

Donovan, S., Clayton, A., Beeharry, M., et al (2000) Deliberate self-harm and antidepressant drugs. Investigation of a possible link. British Journal of Psychiatry 177, 551556.CrossRefGoogle ScholarPubMed
Khan, A., Warner, H. A. & Brown, W. A. (2000) Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials. Archives of General Psychiatry, 57, 311317.CrossRefGoogle ScholarPubMed
Markowitz, J. C. (2001) Antidepressants and suicide risk. british Journal of Psychiatry, 178, 477.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.
You have Access

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Response from GlaxoSmithKline
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

Response from GlaxoSmithKline
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

Response from GlaxoSmithKline
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *